Treace Medical Concepts, Inc.
TMCI· Nasdaq
Released Aug 7, 2025, after the close
10-Q filed Aug 7, 2025, 38 days after period end · 0000950170-25-105059
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $47.39M | $44.46M | $41.95M | $29.97M |
| Net Income | -$17.40M | -$21.21M | -$12.27M | -$17.23M |
| EPS Diluted |
Treace Medical Concepts, Inc. · CIK 1630627 · Engraved from SEC EDGAR
| -$0.28 |
| -$0.34 |
| -$0.20 |
| -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.